Navigation Links
Neurocrine Biosciences Reports Third Quarter 2011 Results
Date:10/31/2011

aterially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's R & D pipeline and the Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's R & D pipeline include risk that elagolix, the company's lead clinical program, will fail to demonstrate that elagolix is safe and effective; risk that elagolix Phase III clinical trials will be delayed for regulatory or other reasons; and risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that the Company's urocortin 2 and VMAT2 clinical candidates will not proceed to later stage clinical trials; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended June 30, 2011. Ne
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... the "Global Cell Therapy Market Outlook 2020 " ... cell therapy in tissue and regenerative medicine is expected ... other options which could help in the growth of ... segment but they are unable to form new tissue ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... March 8, 2011 Leading events organiser UBM Live ... ., today announced details of the anticipated content and new ... a leading International pharmaceutical event, being held from 18-20 April, ... full line-up of events surrounding CPhI Japan includes P-MEC Japan, ...
... ALCLS), the genome engineering specialist, and Etablissement Francais du ... France, announce that StemRed, an ambitious collaborative program to ... (iPS cells) has started on March 1. ... Curie University (UPMC), Bertin Technologies and CECS (Centre d,Etude ...
... In addition to reliable high efficiency transfection reagents, Mirus ... of the Reagent Agent(SM) - a new online tool ... any nucleic acid into any cell type, including hard-to-transfect ... on extensive in-house transfection and electroporation data, customer feedback, ...
Cached Biology Technology:UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4Cellectis and the Etablissement Francais du Sang Launch StemRed, a Program to Produce Red Blood Cells From Stem Cells 2Reagent Agent(SM) Transfection Cell Line Database From The Transfection Experts 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... similar situations change as they age, according to a ... brain scanning, eye-tracking and behavioral measures to understand how ... preschool children and adults distinguish between damage done either ... done something wrong. Nonetheless, adults are much less likely ...
... studies were limited mostly to the movement of sick ... Professor of Systematic Zoology and Evolutionary Biology. To change ... study about the locomotion of healthy dogs in 2006 ... technical effort the scientists measured, documented and compared the ...
... NEW YORK, NY (May 26, 2011) The New ... dedicated to advancing cures for major diseases through stem ... University scientists, led by NYSCF Robertson Investigator Dr. ... humans into functional neurons. These neurons will ...
Cached Biology News:Changes in brain circuitry play role in moral sensitivity as people grow up 2Changes in brain circuitry play role in moral sensitivity as people grow up 3Dogs in motion 2Dogs in motion 3
...
... The FDSS6000 System is an ... assays, assay development and high throughput ... and luminescence modalities., The Hamamatsu light ... highlight our companys decades-long experience in ...
... are designed for enhanced translation of cloned sequences ... reticulocyte lysate. The maps for pCITE-2b(+) and pCITE-2c(+) ... exceptions: pCITE-2b(+) is a 3793 bp plasmid; it ... Xcm I sites. Subtract 7 bp from all ...
... White walled plates enhance luminescent signals ... fluorescence,• Not treated (or medium binding) ... and binds biomolecules through passive interactions,• ... of large molecules, such as antibodies, ...
Biology Products: